[go: up one dir, main page]

MX384073B - Una composicion farmaceutica para reducir la grasa localizada y sus usos. - Google Patents

Una composicion farmaceutica para reducir la grasa localizada y sus usos.

Info

Publication number
MX384073B
MX384073B MX2018002462A MX2018002462A MX384073B MX 384073 B MX384073 B MX 384073B MX 2018002462 A MX2018002462 A MX 2018002462A MX 2018002462 A MX2018002462 A MX 2018002462A MX 384073 B MX384073 B MX 384073B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
reducing localized
localized fat
fat
drug
Prior art date
Application number
MX2018002462A
Other languages
English (en)
Other versions
MX2018002462A (es
Inventor
Yu- Fang Ling
Original Assignee
Caliway Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58186932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX384073(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/CN2015/088340 external-priority patent/WO2016029870A1/zh
Application filed by Caliway Biopharmaceuticals Co Ltd filed Critical Caliway Biopharmaceuticals Co Ltd
Publication of MX2018002462A publication Critical patent/MX2018002462A/es
Publication of MX384073B publication Critical patent/MX384073B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona una composición farmacéutica para reducir la grasa localizada, que comprende micelas que contienen medicamento elaboradas de tensioactivos, y curcumina encapsuladas en las micelas que contienen medicamento. Esta composición farmacéutica para reducir la grasa localizada puede reducir la grasa en el sitio de administración y tiene las ventajas de alta estabilidad, alta biodisponibilidad para el tejido graso, pocos efectos secundarios y liberación sostenida.
MX2018002462A 2015-08-28 2016-08-26 Una composicion farmaceutica para reducir la grasa localizada y sus usos. MX384073B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/CN2015/088340 WO2016029870A1 (zh) 2014-08-28 2015-08-28 用于减少局部脂肪与减少体重的组合物及其医药品与应用
US201562257846P 2015-11-20 2015-11-20
US201662299702P 2016-02-25 2016-02-25
PCT/IB2016/055102 WO2017037594A2 (zh) 2015-08-28 2016-08-26 用于减少局部脂肪的医药组成物及其用途

Publications (2)

Publication Number Publication Date
MX2018002462A MX2018002462A (es) 2018-06-19
MX384073B true MX384073B (es) 2025-03-11

Family

ID=58186932

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018002462A MX384073B (es) 2015-08-28 2016-08-26 Una composicion farmaceutica para reducir la grasa localizada y sus usos.
MX2018002461A MX387266B (es) 2015-08-28 2016-08-26 Una composicion farmaceutica para reducir la grasa localizada y sus usos
MX2021010359A MX2021010359A (es) 2015-08-28 2018-02-27 Una composicion farmaceutica para reducir la grasa localizada y sus usos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2018002461A MX387266B (es) 2015-08-28 2016-08-26 Una composicion farmaceutica para reducir la grasa localizada y sus usos
MX2021010359A MX2021010359A (es) 2015-08-28 2018-02-27 Una composicion farmaceutica para reducir la grasa localizada y sus usos.

Country Status (23)

Country Link
US (4) US10610496B2 (es)
EP (3) EP3381473A4 (es)
JP (5) JP7063804B2 (es)
KR (4) KR102240221B1 (es)
CN (4) CN119157850A (es)
AU (5) AU2016314545C1 (es)
BR (2) BR112018003892A2 (es)
CA (2) CA2995158C (es)
CO (1) CO2018003424A2 (es)
DK (1) DK3381451T3 (es)
ES (1) ES3041835T3 (es)
FI (1) FI3381451T3 (es)
HR (1) HRP20251142T1 (es)
IL (1) IL257784B2 (es)
LT (1) LT3381451T (es)
MX (3) MX384073B (es)
PL (1) PL3381451T3 (es)
PT (1) PT3381451T (es)
RU (1) RU2753507C2 (es)
SG (1) SG11201801111RA (es)
SM (1) SMT202500365T1 (es)
TW (3) TWI604859B (es)
WO (2) WO2017037593A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10537548B2 (en) 2014-08-28 2020-01-21 Caliway Biopharmaceuticals Co., Ltd. Composition and medical product for reducing body weight and body fat, and use of said product
US11318110B2 (en) 2015-08-28 2022-05-03 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition for reducing local fat and uses thereof
CN119157850A (zh) * 2015-08-28 2024-12-20 康霈生技股份有限公司 用于减少局部脂肪的医药组成物及其用途
KR20190040305A (ko) 2016-08-26 2019-04-17 칼리웨이 바이오파마슈티칼스 코., 엘티디. 체중 감소를 위한 피하 주사제 및 그의 용도
WO2018094253A1 (en) 2016-11-18 2018-05-24 Pacira Pharmaceuticals, Inc. Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same
TWI676476B (zh) * 2017-03-28 2019-11-11 康霈生技股份有限公司 用於減少體重及減少體脂肪的組合物及其醫藥品與應用
US12128011B2 (en) 2019-02-11 2024-10-29 Joseph Halstead Therapeutically administrable high dose non-aqueous curcuminoid solutions
US20220184170A1 (en) 2019-03-24 2022-06-16 NaishadhKumar Ramubhai Patel Formulation to enhance the bioavailibity and stability of curcuminoids and/or its derivatives thereof
CN110934827B (zh) * 2019-11-08 2021-03-19 江西中医药大学 一种口服葛根素混合胶束制剂、制备方法及应用
CN113730650B (zh) * 2021-10-13 2022-11-01 哈尔滨泽润医疗机构管理有限公司 一种碳水溶酶组合物及其制备方法和应用
KR102691705B1 (ko) * 2021-10-25 2024-08-06 주식회사 지엘케이인터내셔날 지방 분해용 조성물
CN119255715A (zh) * 2022-03-28 2025-01-03 路易斯安娜州立大学监测委员会，农业和机械学院 用于提高胰岛素敏感性的协同作用
US12111372B2 (en) 2022-04-25 2024-10-08 GE Precision Healthcare LLC Wireless coil adaptor for a magnetic resonance imaging system
IL316237A (en) * 2022-05-16 2024-12-01 Caliway Biopharmaceuticals Co Ltd Preparations and methods for relieving conditions caused by an abnormal layer of adipose tissue or subcutaneous fat
US20240165050A1 (en) * 2022-11-22 2024-05-23 Caliway Biopharmaceuticals Co., Ltd. Method for treating and/or preventing edematous fibrosclerotic panniculopathy
WO2025231431A1 (en) * 2024-05-03 2025-11-06 Amalfi Bio, Inc. Methods for reducing fatty infiltration

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
RU2250763C2 (ru) * 1999-03-03 2005-04-27 Эли Лилли Энд Компани Фармацевтические препараты эхинокандина, содержащие мицелообразующие поверхностно-активные вещества
EP1077211B1 (en) * 1999-08-16 2006-11-22 DSM IP Assets B.V. Process for the production of epigallocatechin gallate
US6475530B1 (en) 2000-05-31 2002-11-05 Eric H. Kuhrts Methods and compositions for producing weight loss
US6383482B1 (en) * 2000-08-24 2002-05-07 Vitacost.Com, Inc. Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
US20040071799A1 (en) 2001-02-12 2004-04-15 Xiurong Xu Herbal compositions and methods for effecting weight loss in humans
JP4179494B2 (ja) 2001-10-23 2008-11-12 株式会社カネカ ペルオキシソーム増殖剤応答性受容体リガンド剤
US20040146539A1 (en) 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
CN1809288A (zh) 2003-06-04 2006-07-26 雀巢技术公司 体重管理饮料
CN100539988C (zh) * 2003-06-27 2009-09-16 株式会社太平洋 含有生理活性成分的自聚集聚合物纳米颗粒和含有该纳米颗粒的外用搽剂
CN101247793B (zh) 2003-12-29 2013-04-10 哈佛大学校长及研究员协会 治疗或预防肥胖和胰岛素抗性病症的组合物
US20050232974A1 (en) 2004-04-19 2005-10-20 Gore Makarand P System and a method for pharmaceutical dosage preparation using jettable microemulsions
US20050267221A1 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
CN100486567C (zh) * 2004-08-12 2009-05-13 山东绿叶天然药物研究开发有限公司 姜黄素乳剂及其制备方法
WO2006074278A2 (en) 2005-01-05 2006-07-13 Mitsunori Ono Compositions for treating diabetes or obesity
EP2520183B1 (de) * 2005-02-04 2017-07-05 Peter Heger Verwendung einer hydroxystilben-haltigen Wirkstoffkombination zur Behandlung von Depressionen und Angstzuständen
ITFI20050031A1 (it) 2005-02-21 2006-08-22 Stefan Coccoloni Una composizione farmaceutica atta a prevenire l'invecchiamento e l'insorgere di malattie vascolari,neoplastiche,cutanee e dell'apparato pilifero
WO2007011743A2 (en) 2005-07-14 2007-01-25 Lipothera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
JP2007063137A (ja) * 2005-08-29 2007-03-15 Daicho Kikaku:Kk 抗肥満薬
WO2007041276A2 (en) 2005-09-29 2007-04-12 New Chapter, Inc. Methods for modulating apoptosis, cellgrowth, and protein expression with herbal compositions
JP2007131603A (ja) 2005-11-14 2007-05-31 Kaneka Corp Ｌ−カルニチン合成系酵素遺伝子の転写促進用組成物
CN100367951C (zh) * 2005-12-16 2008-02-13 石药集团恩必普药业有限公司 丁苯酞静脉乳剂及其应用
EP1993365B1 (en) * 2006-03-06 2013-05-08 The Regents of the University of California Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders
EA200802090A1 (ru) 2006-03-31 2010-04-30 ДСМ АйПи АССЕТС Б.В. Новое применение соединений и комбинаций соединений для улучшения внешнего вида
US7977319B1 (en) 2006-04-03 2011-07-12 Scott David Levine Ultra-high fiber supplement and method of reducing weight, cardiovascular risks and ingested toxins
WO2007113008A2 (en) * 2006-04-04 2007-10-11 Dsm Ip Assets B.V. Opaque container comprising food or pharmaceutical products or herbal(s)
CN101095665A (zh) 2006-06-27 2008-01-02 中国科学院上海生命科学研究院 Sirt1在预防、控制或治疗肥胖中的用途
US7923026B2 (en) * 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
KR101069502B1 (ko) * 2006-10-31 2011-09-30 (주)아모레퍼시픽 비만 및 당뇨병 개선용 경구용 조성물
JP2008133272A (ja) * 2006-10-31 2008-06-12 Ito En Ltd Ｃｐｔ活性亢進剤及び飲食物
CN101310718A (zh) * 2007-05-23 2008-11-26 中国科学院上海生命科学研究院 减肥降血脂的含儿茶素的组合物及其用途
CN102357226B (zh) 2007-08-07 2013-07-10 北京北大维信生物科技有限公司 中草药姜黄的醇提取物在制备具有脂肪酶活性抑制作用的药物中的应用
WO2009066303A2 (en) * 2007-11-22 2009-05-28 Ganga Raju Gokaraju New synergistic phytochemical composition for the treatment of obesity
WO2009089011A2 (en) * 2008-01-08 2009-07-16 Sirtris Pharmaceuticals, Inc. Resveratrol formulations
TW201006474A (en) 2008-04-18 2010-02-16 Reata Pharmaceuticals Inc Natural products including an anti-flammatory pharmacore and methods of use
AU2009262729B2 (en) * 2008-06-25 2013-11-14 Elc Management Llc Method and compositions for improving skin and body appearance
WO2010048114A1 (en) 2008-10-22 2010-04-29 Metaproteomics, Llc Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis
US8496974B2 (en) * 2008-11-25 2013-07-30 Oy Granula Ab Ltd Method for preparing a composition comprising a compound mixture and a carrier agent
CA2748344A1 (en) 2008-11-26 2010-06-03 Lipoprotein Technologies, Inc. Enhanced bioactive formulations of resveratrol
RU2532384C2 (ru) * 2009-03-20 2014-11-10 Байокстракт С.А. Фармацевтическая композиция, проявляющая противовоспалительные свойства
CN101874763A (zh) * 2009-04-29 2010-11-03 上海家化联合股份有限公司 一种白藜芦醇柔性脂质体及其制备方法
KR20100124519A (ko) * 2009-05-19 2010-11-29 (주)아모레퍼시픽 녹차 추출물을 함유하는 조성물
CN101632655B (zh) 2009-08-04 2011-12-07 南京大渊美容保健有限公司 延缓衰老的白藜芦醇和生物类黄酮营养组合物
JP5594819B2 (ja) 2009-12-22 2014-09-24 キリンホールディングス株式会社 脂質代謝改善用組成物
EA021570B1 (ru) * 2010-03-10 2015-07-30 Эббви Бахамаз Лтд. Твердые композиции для лечения инфекции hcv (варианты)
US8835509B2 (en) * 2010-05-31 2014-09-16 Arbro Pharmaceuticals Ltd. Self emulsifying drug delivery system for a curcuminoid based composition
US20130245118A1 (en) * 2010-07-02 2013-09-19 Eric H. Kuhrts Stable fatty acid-containing formulations
MY156618A (en) 2010-07-02 2016-03-15 Helix Biomedix Inc N-acyl amino acid derivatives for treating skin conditions such as cellulite
KR101640258B1 (ko) * 2010-07-05 2016-07-15 주식회사 엘지생활건강 적포도 추출물, 녹차 추출물, 대두 추출물 및 ｌ－카르니틴을 유효성분으로 함유하는 항비만 조성물
US20130143869A1 (en) 2010-07-16 2013-06-06 Merz Pharma Gmbh & Co. Kgaa Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction of subcutaneous adipose tissue
WO2012050978A1 (en) * 2010-09-29 2012-04-19 MyCell Holdings Limited Formulations of ubiquinol and resveratrol esters
CN102106816A (zh) * 2010-12-16 2011-06-29 天津迈迪瑞康生物医药科技有限公司 一种白藜芦醇纳米制剂及其制备方法
US8815310B2 (en) 2011-01-10 2014-08-26 Morteza Naghavi Compositions for boosting metabolism, assisting weight loss, and promoting cardiovascular health
CN102512404B (zh) 2011-11-18 2014-05-07 上海交通大学 一种姜黄素类化合物肺靶向制剂及其制备方法与应用
WO2013100111A1 (ja) 2011-12-27 2013-07-04 油田 正樹 サーチュイン活性化剤
ES2739194T3 (es) * 2012-01-19 2020-01-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulación y método para aumentar la biodisponibilidad oral de fármacos
US8496979B1 (en) 2012-02-02 2013-07-30 Reliv International, Inc. Caffeine-free dietary supplements for increasing energy and methods of administering the same
MX2014009308A (es) 2012-02-29 2014-10-14 Avon Prod Inc Uso de moduladores de cpt-1 y composiciones de los mismos.
US8652518B2 (en) 2012-04-15 2014-02-18 Jahahreeh Finley Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
US9731015B2 (en) 2012-08-04 2017-08-15 Eric Hauser Kuhrts Water-soluble lipophilic natural compound formulations
WO2014028607A1 (en) * 2012-08-14 2014-02-20 Abbott Laboratories Low glycemic index nutritional compositions for preserving muscle mass and improving body composition in diabetics
US9211298B2 (en) 2012-11-16 2015-12-15 Song Gao Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses
DE202012012130U1 (de) * 2012-12-19 2014-03-21 Aquanova Ag Curcuminsolubilisat
WO2014138426A2 (en) * 2013-03-07 2014-09-12 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
CN103285401A (zh) * 2013-05-27 2013-09-11 沈阳药科大学 一种能提高难溶性药物溶解性和生物利用度的组合物
US9458086B1 (en) * 2013-07-03 2016-10-04 University Of South Florida (A Florida Non-Profit Corporation) Compositions and methods for adipocyte modulation
WO2015072602A1 (ko) 2013-11-15 2015-05-21 (주)다미화학 난용성 물질의 수용액 가용화 조성물 및 이를 이용한 난용성 물질의 수용액 가용방법
EP3074028B1 (en) * 2013-11-27 2022-04-06 Research Foundation Of The City University Of New York Activity enhancing curcumin compositions and methods of use
TW201540294A (zh) * 2014-04-25 2015-11-01 康立為生醫科技股份有限公司 用於抑制脂肪細胞、降低體脂肪、減少體重或促進脂肪代謝之植物萃取組成物及其醫藥組合物與用途
CN103989659B (zh) * 2014-05-26 2016-09-07 重庆医科大学 姜黄素纳米结构脂质载体及其制备方法
EP3187178B1 (en) * 2014-08-28 2022-06-08 Caliway Biopharmaceuticals Co. Ltd. Composition and pharmaceuticals for reducing localized fat and body weight and the use thereof
US10226503B2 (en) 2014-08-28 2019-03-12 Caliway Biopharmaceuticals Co., Ltd. Plant extract composition for reducing topical fat and promoting weight loss as well as applications thereof
WO2016029868A1 (zh) * 2014-08-28 2016-03-03 康霈生技股份有限公司 用于减少体重及减少体脂肪的组合物及其医药品与应用
US11318110B2 (en) 2015-08-28 2022-05-03 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition for reducing local fat and uses thereof
CN119157850A (zh) 2015-08-28 2024-12-20 康霈生技股份有限公司 用于减少局部脂肪的医药组成物及其用途
KR20190040305A (ko) 2016-08-26 2019-04-17 칼리웨이 바이오파마슈티칼스 코., 엘티디. 체중 감소를 위한 피하 주사제 및 그의 용도

Also Published As

Publication number Publication date
TW201707686A (zh) 2017-03-01
TWI604859B (zh) 2017-11-11
CN108697668B (zh) 2022-11-04
AU2021202349A1 (en) 2021-05-13
RU2753507C2 (ru) 2021-08-17
EP3381451B1 (en) 2025-08-20
EP3381451A4 (en) 2019-10-09
KR20180037058A (ko) 2018-04-10
CN115778928A (zh) 2023-03-14
US11433034B2 (en) 2022-09-06
SMT202500365T1 (it) 2025-11-10
IL257784B2 (en) 2023-11-01
AU2019246808B2 (en) 2021-01-28
KR20180039167A (ko) 2018-04-17
TW201707685A (zh) 2017-03-01
EP3381473A2 (en) 2018-10-03
AU2016314545B2 (en) 2019-07-11
AU2016314546C1 (en) 2021-07-22
JP7063803B2 (ja) 2022-05-09
RU2019108198A (ru) 2020-09-21
CN108697668A (zh) 2018-10-23
IL257784A (en) 2018-06-28
AU2021202349B2 (en) 2022-12-08
EP4647070A2 (en) 2025-11-12
CA2995158C (en) 2021-05-11
RU2019108198A3 (es) 2020-09-21
MX2018002461A (es) 2018-06-07
AU2016314545C1 (en) 2021-09-23
LT3381451T (lt) 2025-10-10
MX387266B (es) 2025-03-18
KR102240221B1 (ko) 2021-04-14
KR20200032768A (ko) 2020-03-26
AU2016314545A1 (en) 2017-11-16
MX2018002462A (es) 2018-06-19
JP7054540B2 (ja) 2022-04-14
TWI630922B (zh) 2018-08-01
AU2019280037A1 (en) 2020-01-16
CA2995155C (en) 2021-05-11
EP3381451A2 (en) 2018-10-03
PT3381451T (pt) 2025-10-01
US20180243211A1 (en) 2018-08-30
US20220362173A1 (en) 2022-11-17
AU2019246808A1 (en) 2019-10-31
WO2017037593A2 (zh) 2017-03-09
CN115778928B (zh) 2025-07-25
JP2018531220A (ja) 2018-10-25
MX2021010359A (es) 2021-10-01
CA2995155A1 (en) 2017-03-09
TW201806584A (zh) 2018-03-01
KR102356390B1 (ko) 2022-02-08
CA2995158A1 (en) 2017-03-09
SG11201801111RA (en) 2018-03-28
PL3381451T3 (pl) 2025-11-12
AU2016314546A1 (en) 2018-03-01
WO2017037594A3 (zh) 2018-08-23
US10610496B2 (en) 2020-04-07
JP2018533545A (ja) 2018-11-15
KR102107917B1 (ko) 2020-05-08
EP3381473A4 (en) 2019-10-09
HRP20251142T1 (hr) 2025-11-21
ES3041835T3 (en) 2025-11-14
CN119157850A (zh) 2024-12-20
US20180250243A1 (en) 2018-09-06
JP2020128404A (ja) 2020-08-27
FI3381451T3 (fi) 2025-10-10
JP7063804B2 (ja) 2022-05-09
JP2019528297A (ja) 2019-10-10
JP2020143091A (ja) 2020-09-10
TWI667044B (zh) 2019-08-01
WO2017037594A2 (zh) 2017-03-09
CN109069655A (zh) 2018-12-21
AU2016314546B2 (en) 2019-09-12
BR112018003877A2 (pt) 2018-09-25
CN109069655B (zh) 2024-09-27
KR20200049882A (ko) 2020-05-08
JP7095903B2 (ja) 2022-07-05
US20200163906A1 (en) 2020-05-28
CO2018003424A2 (es) 2018-07-10
AU2019280037B2 (en) 2021-02-18
IL257784B1 (en) 2023-07-01
WO2017037593A3 (zh) 2018-08-23
DK3381451T3 (da) 2025-10-06
US12357588B2 (en) 2025-07-15
BR112018003892A2 (pt) 2018-09-25

Similar Documents

Publication Publication Date Title
MX384073B (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
SV2018005610A (es) Derivados de oxopiridina sustituidos
EP3600563C0 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING VITAMIN D3 AND HYALURONIC ACID
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
CL2015002335A1 (es) Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas.
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
MX2015014656A (es) Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas.
MX2017003561A (es) Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos.
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
CO2017006958A2 (es) Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para la preparación y uso de los mismos
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
BR112018072113A2 (pt) excipiente à base de proteínas para ingredientes farmacêuticos ativos
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
MX384254B (es) Formulaciones para mejorar la eficacia de farmacos hidrofobicos.
MX389461B (es) Composiciones que comprenden una matriz de polisacarido para la liberacion controlada de ingredientes activos
CL2016000543A1 (es) Uso de pidotimod o sus estereoisómeros y/o sales fisiológicamente aceptables para preparar un medicamento útil en el tratamiento de enfermedades asociadas con la inflamación, donde hay una hiperactivación aberrante de la vía no canónica de nfkb.
CL2015001308A1 (es) Pastilla medicinal para chupar a base de ibuprofeno sodico dihidratado; metodo de preparación y el uso en el tratamiento de los trastornos orofaringeos.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
CU20160119A7 (es) Formulaciones tópicas de heparina
UY38033A (es) Combinaciones de lípidos